Among bioactive peptides, cationic antimicrobial peptides (AMPs), also referred to as host defence peptides (HDPs), are valuable tools to treat infections, being able to kill a wide variety of microbes directly and/or modulate host immunity. HDPs have great therapeutic potential against antibiotic-resistant bacteria, viruses and even parasites. However, high manufacturing costs have greatly limited their development as drugs, thus highlighting the need to develop novel and competitive production strategies. Here, a cost-effective procedure was established to produce the high amounts of peptides required for basic and clinical research. Firstly, a novel culture medium was designed, which was found to support significantly higher cell densities and recombinant expression levels of peptides under test compared to conventional media. The procedure has been also efficiently scaled up by using a 5 L fermenter, while the costs have been lowered significantly by developing a successful auto-induction strategy, which has been found to support higher yields of target constructs and cell biomass compared to conventional strategies based on expression induction by IPTG. Interestingly, it was estimated that by increasing production scale from 100 to 1000 mg/batch, unit costs decreased strongly from 253 to 42 €/mg. These costs appear highly competitive when compared to chemical synthesis strategies. Altogether, the data indicate that the strategy represents an important starting point for the future development of large-scale manufacture of HDPs. © 2019 Elsevier B.V.

Cost-effective production of recombinant peptides in Escherichia coli / Gaglione, Rosa; Pane, Katia; Dell'Olmo, Eliana; Cafaro, Valeria; Pizzo, Elio; Olivieri, Giuseppe; Notomista, Eugenio; Arciello, Angela. - In: NEW BIOTECHNOLOGY. - ISSN 1871-6784. - 51:(2019), pp. 39-48. [10.1016/j.nbt.2019.02.004]

Cost-effective production of recombinant peptides in Escherichia coli

Gaglione, Rosa
Primo
;
Pane, Katia;Dell'Olmo, Eliana;Cafaro, Valeria;Pizzo, Elio;Notomista, Eugenio;Arciello, Angela
Ultimo
2019

Abstract

Among bioactive peptides, cationic antimicrobial peptides (AMPs), also referred to as host defence peptides (HDPs), are valuable tools to treat infections, being able to kill a wide variety of microbes directly and/or modulate host immunity. HDPs have great therapeutic potential against antibiotic-resistant bacteria, viruses and even parasites. However, high manufacturing costs have greatly limited their development as drugs, thus highlighting the need to develop novel and competitive production strategies. Here, a cost-effective procedure was established to produce the high amounts of peptides required for basic and clinical research. Firstly, a novel culture medium was designed, which was found to support significantly higher cell densities and recombinant expression levels of peptides under test compared to conventional media. The procedure has been also efficiently scaled up by using a 5 L fermenter, while the costs have been lowered significantly by developing a successful auto-induction strategy, which has been found to support higher yields of target constructs and cell biomass compared to conventional strategies based on expression induction by IPTG. Interestingly, it was estimated that by increasing production scale from 100 to 1000 mg/batch, unit costs decreased strongly from 253 to 42 €/mg. These costs appear highly competitive when compared to chemical synthesis strategies. Altogether, the data indicate that the strategy represents an important starting point for the future development of large-scale manufacture of HDPs. © 2019 Elsevier B.V.
2019
Cost-effective production of recombinant peptides in Escherichia coli / Gaglione, Rosa; Pane, Katia; Dell'Olmo, Eliana; Cafaro, Valeria; Pizzo, Elio; Olivieri, Giuseppe; Notomista, Eugenio; Arciello, Angela. - In: NEW BIOTECHNOLOGY. - ISSN 1871-6784. - 51:(2019), pp. 39-48. [10.1016/j.nbt.2019.02.004]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S187167841730691X-main definitivo.pdf

Open Access dal 01/03/2020

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 4.45 MB
Formato Adobe PDF
4.45 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/743186
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 52
social impact